Arsenic trioxide as a radiation sensitizer for (131)I-metaiodobenzylguanidine therapy: Results of a phase II study

Arsenic trioxide has in vitro and in vivo radiosensitizing properties. We hypothesized that Arsenic trioxide would enhance the efficacy of the targeted radiotherapeutic agent (131)I-metaiodobenzylguanidine ((131)I-MIBG), and tested the combination in a phase II clinical trial. METHODS: Patients with...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:J Nucl Med
Päätekijät: Modak, Shakeel, Zanzonico, Pat, Carrasquillo, Jorge A., Kushner, Brian H., Kramer, Kim, Cheung, Nai-Kong V., Larson, Steven M., Pandit-Taskar, Neeta
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: 2016
Aiheet:
Article
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4976822/
https://ncbi.nlm.nih.gov/pubmed/26742708
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2967/jnumed.115.161752
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia